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We created a rabbit model of retinoblastoma and conﬁrmed the tumor clinically and histopathologically. Seventeen New Zealand
rabbits were immunosuppressed with cyclosporin A at doses of 10–15mg/kg. At day 3, the animals received a 30µls u b r e t i n a l
injection of 1 × 106 cultured WERI retinoblastoma cells. Digital fundus images were captured before euthanasia, and the eyes
were submitted for histopathology. Retinoblastoma cells grew in all the inoculated eyes and established a tumor under the retina
and/or in the vitreous. New blood vessels in the tumor were observed starting at week 5. Cuﬀs of viable tumor cells surrounded
the blood vessels with regions of necrosis present at 70–80 µm from nutrient vessels. Occasional tumor seeds in the vitreous
histologically exhibited central necrosis. This rabbit model demonstrated similar fundus appearance and pathologic features to
human retinoblastoma and may be used as a model to test various routes of drug delivery for retinoblastoma.
1.Introduction
Retinoblastoma is the most common primary intraocular
tumor in childhood with an incidence of 1 in 20,000
live births. When left untreated, retinoblastoma is almost
always fatal, but more than 95% of patients survive if
they are treated before the tumor spreads outside the eye.
Retinoblastoma is initiated by mutations in both alleles
of the RB1 tumor suppressor gene. In about half of the
children, thedisease ishereditary, causinga predisposition to
bilateral retinoblastoma and a risk of second malignancies.
This risk of second malignancies is greater than 50% by
the age of 50 years if the retinoblastoma is treated with
external beam radiation (EBRT) [1], particularly in children
less than 1 year of age [2]. Anticancer chemotherapeutic
agents such as cyclophosphamide might have contributed to
the high incidence ofsecondary tumors in children with RB1
mutationswho also received EBRT[3]. Radiation also causes
orbital deformities and cataracts if the tumor is located
anteriorly.
Small, localized tumors can sometimes be treated using
laser therapy or cryotherapy. Systemic chemotherapy can
cause signiﬁcant systemic toxicitylike secondary leukemiaor
secondary malignancy, even if the complication rates remain
acceptable [4, 5]. Prolonged use of chemotherapy, especially
at higher doses, may be associated with the development of
multidrug resistance [6]. Delivery of drug locally to the eye
has been suggested with high eﬃcacy and limited systemic
toxicity [7], but it can be associated with toxicity to the
surrounding ocular tissues [8].
Animal models of retinoblastoma have been developed
to study new therapies for this disease. A transgenic murine
model of retinoblastoma has been introduced [9], but it is
not available in larger animals.
Our goal was to create a rabbit model for retinoblastoma
to study transscleral drug delivery. The main advantage for
the use of rabbits is their larger eye size, which may serve as
a model for local, targeted drug delivery platforms to human
eyes with retinoblastoma. Blanco and coworkers developed
a rabbit ocular melanoma model by injecting human
uveal melanoma cells into the eyes of immunosuppressed
rabbits [10]. The rabbits were immunosuppressed by daily
intramuscular injection of cyclosporin, and cultured human
uveal melanoma cells were injected into the suprachoroidal
space of the rabbit eyes. Eighty-nine percent of the animals
showed intraocular tumors starting 1 week after injection.2 Journal of Biomedicine and Biotechnology
Additionally, an animal model of retinoblastoma has been
developed by injecting cultured human retinoblastoma cells
into the vitreal cavities of immunodeﬁcient mice [11].
2.Methodsand Materials
2.1.Animals andInductionofImmunosuppression. Allanimal
procedures were approved by Institutional Animal Care and
Use Committee of Emory University and conformed to
the Association for Research in Vision and Ophthalmology
statement for the Use of Animals in Ophthalmic and Vision
Research. Seventeen male New Zealand albino rabbits with a
mean initial weight around 3kg were used in this study. The
rabbits were immunosuppressed with daily intramuscular
injections of cyclosporin A (CsA; Sandimmune 50mg/mL;
Novartis Pharmaceuticals, Cambridge, MA, USA). CsA
administration was maintained throughout the 8-week
experiment to prevent spontaneous tumor regression. The
dosage schedule was 15mg/kg per day for 3 days before cell
inoculation and for 4 weeks thereafter, followed by 10mg/kg
perda yforthelast4w eeksoftheexperiment[10].CsAdoses
wereadjustedweeklyaccordingtoeachanimal’sbodyweight.
Duringthe8-weekfollowup,theanimalsweremonitored
daily for signs of CsA toxicity such as gingival hypertrophy,
drooling, diarrhea, and weight loss.
2.2. Retinoblastoma Cell Line and Cell Culture. The human
retinoblastoma WERI-Rb cells (ATCC HTB-169; American
Type Culture Collection, Manassas, VA, USA) were cultured
in RPMI 1640 medium with 2mM L-glutamine adjusted to
contain 1.5g/L sodium bicarbonate, 4.5g/L glucose, 10mM
HEPES, and 1.0mM sodium pyruvate, and 10% fetal bovine
serum.Thecellsw er egr owninsuspensionataconcentration
of 105-106 cells/ml.
2.3. Cell Injection Procedure. At day 3, the animals received a
30 µl subretinal injection of cultured WERI retinoblastoma
cells (1.5 × 106 cells). The procedure was performed under
general anesthesia after intramuscular injection of Xylazine
and Ketamine. The right eye (study eye) of each rabbit
was dilated and anesthetized by application of Tropicamide
(0.1%) and Proparacaine (0.5%), respectively. The surgery
was performed with a surgical microscope (M691; Wild
Heerbrugg, Heerbrugg, Switzerland) using a contact lens.
This allowed for direct visualization of the fundus through
the dilated pupil during injection of retinoblastoma cells.
The eye was proptosed with a forceps and a sclerotomy was
performed with a 25-gauge blade at the ora serrata at 2
o’clock position 2mm from the limbus. A 50µlH a m i l t o n
syringe with a 30-gauge blunt needle was inserted through
the sclerotomy under microscopic direction until the retina
was reached and subsequently perforated. A freshly prepared
suspension (30µl) of cultured human WERI retinoblastoma
cells (1.5 × 106 cells) was injected into the subretinal space.
The blunt needle was removed and the eye was examined
for any signs of retinal detachment and possible intraretinal
and/or intravitreal hemorrhage. A drop of 0.3% gentamicin
eyedrop was applied to the right eye.
2.4. Ultrasound Examination. At week 4 after intraocular
tumor inoculation, the rabbits were anesthetized with a
mixture of Ketamine and Xylazine and ultrasound examina-
tion was performed on the right eye using 10-MHz B-scan
(Compact Touch; Quantel Medical, Bozeman, MT).
2.5. Tissue Collection and Histopathologic Evaluation. Two
rabbits were sacriﬁced each week until postoperatively 8
weeks with overdose of sodium pentobarbital (65mg/kg).
Digital fundus images were captured prior to euthanasia.
Afterdeath,botheyeswere enucleatedand immediately ﬁxed
in 10%formalin. Theeyeswere serially sectionedandstained
with hematoxylin-eosin. Light microscopic examination was
performed on all histopathologic sections to evaluate the
presence and extent of the tumor in the eye. The eyes were
also evaluated for any evidence of extrascleral extension or
optic nerve involvement of the tumor.
3.Results
The rabbits tolerated daily injection of CsA fairly well with
occasional minor signs of CsA toxicity including gingival
hypertrophy and drooling. One out of seventeen rabbits had
to be sacriﬁced earlier than planned schedule at week 5
because of acute weight loss.
Subretinal injection of cultured retinoblastoma cells
established a tumor in all the rabbits detectable with fun-
doscopy starting at postinjection week 1 (Figure 1(a)). The
tumors became vascularized starting at week 5 (Figure 1(b)),
and the tumor size continued to increase up to 8 weeks
(Figures 1(c) and 1(d)). The B-scan ultrasound detected the
presence of intraocular tumors in all the rabbits. The tumor
w a so b s e rv e da sal a r g em a s si nt h ep o s t e r i o rp o l ep r o t r u d i n g
into the vitreous cavity (Figure 2).
The histopathological examination showed that the
tumors were present in all of the rabbits which received
the subretinal injection. The rabbit model demonstrated
similar fundus appearance and pathologic featuresto human
retinoblastoma. The cells established a tumor in the sub-
retinal space near the optic nerve and in the vitreous
(Figure 3(a)). Occasional tumor seeds in the vitreous exhib-
ited central necrosis (Figure 3(b)). Cuﬀso fv i a b l et u m o r
cells surrounded the blood vessels with regions of necrosis
beginning 70–80µm from central nutrient vessels (Figures
3(c) and 3(d)). Extrascleral extension of the tumor was not
found in any of the animals.
4.Discussion
Although most eyes with International Classiﬁcation Group
A or B tumors are salvaged with chemoreduction and
consolidation therapy, many eyes with Group C or D
tumors are enucleated. Systemic chemotherapy for advanced
retinoblastoma did not eﬀectively treat the vitreous cavity
[12]. A large number of treatment failures occur because
of the progression of the tumor in the vitreous, where the
concentration of the chemotherapeutic agents is low [13].
The salvage rate with chemotherapy and focal treatment forJournal of Biomedicine and Biotechnology 3
(a) (b)
(c) (d)
Figure 1: Fundus photos at postinjection 1 week (a), 6 weeks (b), 7 weeks (c), and 8 weeks (d). The retinoblastoma cells in the subretinal
spaceestablisheda tumorunder the retina andinthe vitreous. New vesselgrowthinthe tumorwasobservedinvivo startingatpostoperative
week 5.
Figure 2: Ultrasound image at postinjection 6 weeks. The B scan
image shows an intraocular tumor in the posterior pole in a rabbit
eye (white arrow).
eyes with vitreous seeding was low, implicating the need
f o rb e t t e rt r e a t m e n to p t i o nf o rt h i sg r o u po fp a t i e n t s[ 14].
Animalmodelsofretinoblastoma areessentialforidentifying
new therapies. The rabbit eye is similar in size to the human
infant eye, and a rabbit retinoblastoma model is suitable for
targeted drug delivery experiments.
Our rabbit model of retinoblastoma developed a tumor
that closely resembles the human retinoblastoma clinically
and histopathologically. The surgical procedure by experi-
enced personnel caused minimal trauma to the retina, and
there were no surgical complications observed. Minimal
postoperative retinal bleeding was observed (1/17), which
was resolved in a week with conservative management. No
retinal detachments were observed.
Intraocular tumors developed in all of the rabbits,
starting fromweek1.Thetumorslowlygrewundertheretina
and/or in the vitreous and continued to grow until the end
of the study. The histopathological features resembled the
ﬁndings in the human retinoblastoma. The tumor seeds in
the vitreous space exhibited central necrosis, and there were
cuﬀs of viable tumor cells surrounding the blood vessels.
The subretinal tumor was conﬁned to the retina posterior to
the equator, and there was no evidence of invasion into the
anterior compartment or outside of the sclera.
An animal model of retinoblastoma was ﬁrst introduced
by injecting human retinoblastoma cell into the immuno-
compromised mice. It was developed by transplanting Y794 Journal of Biomedicine and Biotechnology
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Figure 3: Histological ﬁndings at postinjection 7 weeks. Tumor was observed under the retina near optic nerve and in the vitreous
(hematoxylin-eosin, ×40, (a)). Occasional tumor seeds in the vitreous exhibited central necrosis (×100, (b)). Cuﬀs of viable tumor cells
surrounded the blood vessels with regions of necrosis beginning 70–80µm from nutrient vessels (×100, (c); ×400, (d)).
human retinoblastoma cells into the ﬂanks of immunocom-
promised mice, but it was not the ideal model because of
obvious anatomic diﬀerences between the adult ﬂank and
the eye [15]. Another model was introduced by injecting
human retinoblastoma cells (Y79 and WERI-Rb) into the
vitreal cavities of immunodeﬁcient mice [11]. Both cell lines
developed an intraocular tumor in the immunodeﬁcient
mice, and WERI-Rb cells were predisposed to invade the
anterior uveal tissues and lens. We did not ﬁnd any evidence
of invasion of the injected WERI-Rb cells into the anterior
uvea and/or anterior chamber in our rabbit model.
Transgenic mice models are widely used as preclinical
models to test new therapies for retinoblastoma. Human
retinoblastoma cellsshow severalgeneticchangesin addition
to Rb inactivation [16], suggesting that Rb loss provides
the capacity to proliferate and that another mutation is
necessary for the dividing cells to be death resistant. From
this observation, several knockout mouse models were
introduced by deleting Rb1 gene and other proteins. Simian
virus large T antigen (Tag) inactivates both RB and p53,
[17], and the LHbeta-Tag mice carry a transgene composed
of the coding region of the SV 40 large T antigen driven by
the promoter of the lutenizing hormone beta-subunit gene,
developing multifocal, bilateral retinal tumors [9]. Other
mouse knockoutmodels were generated, involving mutation
of Rb and p107, [18], Rb, p107 and p53 [19], and Rb
and p130 [20]. However, our rabbit model has advantages
over the mouse models. The main advantage for the use
of rabbits is their larger eye size, which permits a more
accurate injection of the drugs and evaluation of methods
of targeted intraocular drug delivery. Another advantage
is that our model includes vitreous seeds of viable tumor
when the retinal tumor is mid-sized, which are usually
f o u n di nt h el a t es t a g ei nm o u s em o d e l s[ 18, 20]. The
lack of ability to eliminate vitreous seeds is a major reason
of current treatment failures in Group C and D tumors
[12–14]. The major limitations of our model are that we
used commercially available retinoblastoma cell lines, which
may have a diﬀerent drug sensitivity pattern than wild-type
cells. Also, the implanted cells grow from the subretinal
space, not from the retina itself as it would happen in
humans. Therefore, we believe our rabbit model will serve
as a model to test the eﬃcacy of new chemotherapeutic
agents.Journal of Biomedicine and Biotechnology 5
5.Conclusions
Subretinal injection of cultured retinoblastoma cells estab-
lished a tumor in all rabbits in our study. Tumor size
continued to increase up to 8 weeks, and the tumors
became vascularized starting at week 5. The rabbit model
demonstrated similar fundus appearance and pathologic
features to human retinoblastoma, including vitreous seeds
of viable tumor. This rabbit model of retinoblastoma may be
usedasa model toevaluatetheeﬀectivenessofvariousroutes
of drug delivery.
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